eureKARE Plans on Financing

eureKARE is a new company that focuses on financing and building next-generation biotechnology companies in the disruptive fields of the microbiome and synthetic biology. It announced that it launched a $60 million Series A financing. The financing was supported by high-net-worth investors and family offices.

The pioneering new company is focused on two emerging and cutting-edge fields of research that have the potential to disrupt and revolutionize the life sciences industry that is the microbiome and synthetic biology. Nearly 90% of all diseases can be linked to the dysfunction and imbalance of the microbiome with the field forecast to reach $1.6 billion by 2028 at a CAGR of 21%.

Synthetic biology includes gene and cell therapy and industrial applications such as data storage and bioproduction, has seen huge advances in recent years and is expected to have far-reaching implications on the life sciences and other industries and for patients. It is forecast to reach $57 billion by 2028 at a CAGR of 25% per year. Gene therapies already generate c.$4 billion revenues with huge potential in gene editing, siRNA, mRNA, and are forecast to reach c.$10 billion by 2028.

Europe’s scientists are at the forefront of microbiome and synthetic biology research due to the innovative work and thought leadership taking place at prestigious universities and research centers. eureKARE believes that there is a tremendous opportunity to industrialize this translational research by creating bridges between academia and industry.

eureKARE will create 3-5 new ventures a year and invest in 3-5 existing companies. This perfect mix of early-stage ventures with high growth potential and more mature de-risked companies mitigates risk for shareholders. It has a quickly growing portfolio comprising three exciting ventures to date: Stellate Therapeutics in the gut-brain axis field, the XNA technology company Omne Possible and NovoBiome, a discovery program dedicated to the gut-liver axis.